Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea

Evaluation of the Effect of a Vaginal Ring With Meloxicam on Primary Dysmenorrhea in Women of Childbearing Age

The investigators propose that the sustained administration of a vaginal ring would have a better response with respect to pain and a better safety profile than the oral administration of a non-steroidal anti-inflammatory drug.

To assess the relief of the symptoms associated with dysmenorrhea, a specific survey was elaborated that also includes a Visual Analog Scale (VAS) to objectify and measure dysmenorrhea as is the case with McGill's Pain Questionnaire (MPQ).

Inclusion Criteria:

• Regular menstrual cycles on previous 3 months (24-35 days),
• Primary dysmenorrhea on 3 previous months,
• With tubal ligation or users of condom for contraception,
• Hemoglobin of at least 11 g/dl,
• Safety blood analysis in normal levels

Exclusion Criteria:

• Secondary dysmenorrhea,
• Users of hormonal contraceptives (2 months prior to the study) or intrauterine devices (IUDs) (1 month prior the study).
• Allergy to any anti-inflammatory drug including meloxicam or diclofenac.
• Allergy to silicon.
• Pregnant or in lactation.
• Women with untreated or decompensated endocrine disorders